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resumo 
 
 
A doença de Alzheimer (DA) caracteriza-se pela presença de placas amilóides 
e de tranças neurofibrilares, que consistem em acumulações de Abeta e tau 
hiperfosforilada, respectivamente. Concentrações crescentes de Abeta 
precedem o aparecimento de tranças neurofibrilares. Além disso, vários 
estudos sugerem que o aumento da fosfoforilação da APP e da tau no decorrer 
da DA é consequência da neurotoxicidade do Abeta. No entanto, os efeitos 
específicos do Abeta na fosforilação da APP e da tau ainda não foram 
estabelecidos. Há grande abundância de cinases e fosfatases nas sinapses, 
sendo portanto fundamental adoptar um modelo de estudo que as mimetize. 
De facto, os sinaptossomas são actualmente reconhecidos como “sinapses in 
vitro”, e por esse motivo foram o modelo de estudo utilizado. 
Os dados obtidos mostraram um considerável enriquecimento de proteínas 
pré- e pós-sinápticas na fracção sinaptossomal, após o isolamento de 
sinaptossomas. Posto isto, testámos os efeitos do Abeta na viabilidade 
sinaptossomal, tendo-se observado a sua diminuição generalizada, o que 
confirma a toxicidade do péptido. Foi também observado o aumento da 
fosforilação da APP e da tau após o tratamento com Abeta, enquanto que os 
níveis de APP e tau totais permaneceram inalterados, independentemente das 
concentrações de Abeta. Estes resultados sugerem que o Abeta pode 
realmente induzir a hiperfosforilação da APP e da tau. As conclusões retiradas 
desta dissertação são importantes para compreender melhor as vias 
relacionadas com a patogénese da DA. 
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abstract 
 
Alzheimer’s Disease (AD) is characterized by the presence of amyloid plaques 
(APs) and neurofibrillary tangles (NFTs), which consist of Abeta aggregates 
and hyperphosphorylated tau, respectively. It is known that increasing Abeta 
concentrations precede NFT production. Moreover, several lines of evidence 
suggest that the increase in APP and tau phosphorylation is the result of Abeta 
neurotoxicity. Although, the precise effects of the neurotoxic peptide on APP 
and tau phosphorylation remain yet to be fully elucidated. Synapses exhibit 
high concentrations of protein kinases (PKs) and protein phosphatases (PPs). 
Therefore, it is essential to adopt a model system that mimics what happens at 
the synapse. Synaptosomes are actually recognized as “in vitro synapses” and 
for that reason were the model system used. 
Our data revealed that there was a considerable enrichment of pre- and post-
synaptic markers in the synaptosomal fraction after synaptosome isolation. 
Given these results, we went on to test the effects of Abeta on synaptosomal 
viability, which was found to be slightly decreased, confirming the high viability 
of synaptosomes. In addition, we observed the increase of APP and tau 
phosphorylation after Abeta treatment, while holo-APP and total tau levels were 
maintained, independently of Abeta concentrations. These results suggest that 
Abeta can actually induce APP and tau hyperphosphorylation. The conclusions 
attained from this dissertation are important to comprehend the pathways 
related to the pathogenesis of Alzheimer’s disease. 
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1. INTRODUCTION 
 
1.1. Central nervous system 
 
 The nervous system is one of the most intriguing and studied systems of the 
human body. However, there are still many unanswered questions concerning this highly 
organized and vast system. The central nervous system (CNS) consists of the brain and the 
spinal cord, contained within the cranium and the vertebral canal, respectively. Both 
organs are ensheathed by three protective membranes, which are named from outward 
to inward: dura mater, arachnoid, and pia mater. The dura mater is the strongest 
membrane. It is separated from the wall of the vertebral canal by the epidural cavity, 
which contains a quantity of loose areolar tissue and a plexus of veins. Between the dura 
mater and the arachnoid is the subdural cavity, a capillary interval containing a small 
quantity of, possibly, lymphatic fluid. The arachnoid is the most fragile membrane. It is a 
thin, transparent sheath, separated from the pia mater by the subarachnoid cavity, which 
is filled with cerebrospinal fluid. The pia mater closely involves both organs, connecting 
with them by the emission of septa (Gray, 2000).  
 The cerebrum is the largest portion of the brain and comprises the diencephalon 
and telencephalon. The diencephalon consists of the third ventricle and the structures 
that define its boundaries, namely the thalamus, subthalamus, epithalamus and the 
hypothalamus. It is situated in the midline of the brain, and most of its components are 
arranged bilateral and symmetrically. The cerebral hemispheres, two bilateral and 
symmetrical structures, compose the telencephalon. They are crossed by a midline 
sagittal fissure, and are attached by the corpus callosum. Each cerebral hemisphere is 
covered by gray matter, the cerebral cortex, and has a inner core of white matter. Deep 
within the hemispheres are masses of gray matter, the basal nuclei and the lateral 
ventricles. These nuclei consist of the amygdaloid nucleus, the claustrum and corpus 
striatum. The hippocampus is a bilobate structure recognized as a medial bulge in the 
temporal horn of the lateral ventricle, caused by the invagination of the ventricular wall. 
This invagination is the result of the infolding called the hippocampal fissure. The 
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hippocampus acts directly mainly on neighboring areas. However, it can indirectly 
influence more distant regions, such as the hypothalamus, mamillary bodies, and the 
neocortex, via its efferent neurons (Gray, 2000; Greenstein and Greenstein, 2000; Purves, 
2004). 
 The first steps in the study of neurons and their connections in the nervous system 
were taken by Ramon y Cajal (Hammond, 2008). He and a host of successors proposed 
that the cells of the nervous system can be divided in two broad categories: nerve cells, or 
neurons, and supporting cells, neuroglia, or simply glia (Purves, 2004; Siegel and Sapru, 
2005). Glial cells are about 10 times more abundant in the mammalian brain than 
neurons (Mescher, 2010). The former has essential functions in the developing and 
maintenance of the brain, although they are not capable of electric signaling (Purves, 
2004). Rudolph Virchow was the first person proposing the existence of non-neuronal 
tissue in the central nervous system. In 1859, he referred to it as ‘nevroglia’, literally 
meaning ‘nerve glue’, as it was thought to stick neurons together (Binder et al., 2008; 
Hammond, 2008). The term persisted, even though there are no evidences that glial cells 
assist in the binding of neurons. The currently known glial cell roles include maintaining 
the ionic balance of nerve cells, modulating the rate of nerve signal propagation, 
modulating synaptic action by controlling the uptake of neurotransmitters, providing 
scaffold for neural development, and aiding in recovery from neural injuries or in their 
prevention. Glial cells also occupy the spaces between neurons and neuronal processes, 
and separate neurons from blood vessels (Hammond, 2008; Purves, 2004). Concerning 
their location, glia can be classed as central, comprising oligodendrocytes, astrocytes, 
microglia and ependymal cells, or peripheral, just consisting in neurolemmocytes – 
commonly called Schwann cells (Hammond, 2008).  
 
 
1.2. Glial Cells 
 
 Astrocytes (Figure 1) are specific cells to the central nervous system. They possess 
a large number of radiating processes, giving them a starlike appearance. Concerning the 
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number and length of processes, astrocytes can be classified as fibrous astrocytes, with 
few long processes, or protoplasmic astrocytes, with many short, branched processes. 
The former is located in the white matter, while the latter is found in the gray matter. 
Their processes are reinforced with intermediate filaments made of glial fibrillary acid 
protein, which acts as a unique marker. Astrocytes are by far the most numerous glial 
cells and are mainly present in the gray matter. They have three main functions: (1) 
regulation of the ionic composition of the extracellular fluid, (2) maintaining of the blood-
brain barrier in the adult brain, and (3) taking part in the neurotransmitter cycle. 
 
 
Figure 1. Schematic representation of an astrocyte (taken from Mescher, 2010). 
 
 Ependymal cells (Figure 2) are low columnar or cuboidal cells that line the 
ventricles of the brain and the central canal of the spinal cord. In some locations of the 
CNS, the ependymal cells have cilia, which facilitate the cerebrospinal fluid (CSF) 
movement, or microvili, which are thought to be involved in CSF absorption. Ependymal 
cells behave similarly to epithelial cells. However, ependymal cells are not a true 
epithelium, since they do not have a basal lamina. Instead, their basal ends are elongated 
and extend processes into the adjacent neuropil.  
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Figure 2. Ependymal cells lining the central canal of spinal cord (taken from Mescher, 2010). 
 
 Microglia, which are less numerous than the other glial cell types, (Figure 3) are 
small cells with short irregular processes. They derive from hematopoietic precursor cells 
or directly from neural precursor cells. Therefore, they share many properties with 
macrophages found in other tissues. Microglia can freely migrate through the neuropil to 
search for damaged cells and invading microorganisms, secreting a great number of 
immunoregulatory cytokines and constituting the major mechanism of immune defense 
in the CNS. This explains the dramatic increase of the number of microglia following brain 
damage. 
 
 
Figure 3. Schematic representation of a microglial cell (taken from Mescher, 2010). 
 
 Oligodendrocytes (Figure 4), which are also restricted to the CNS, can be divided in 
2 groups: (1) interfascicular oligodendrocytes, found in the white matter where they 
produce the myelin sheath that provides the electrical insulation for some neurons, and 
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(2) satellite oligodendrocytes, which surround neuronal somata in the grey matter. Such 
sheath induces the formation of Na
+
 channels at nodes of Ranvier, therefore allowing the 
faster propagation of Na
+
 action potentials. Oligodendrocytes are the predominant glial 
cell in the CNS white matter. 
 
 
Figure 4. Schematic representation of an oligodendrocyte and its myelin sheaths (taken from Mescher, 
2010). 
 
1.3. Neurons 
 
 Neurons (Figure 5) are specialized cells in intracellular and electrical 
communication, as it is apparent in their morphology. Neurons and glia share the same 
organelles found in all cells. However, in neurons, the organelles are not evenly 
distributed in the distinct regions of the cell. The neuron consists of a cell body 
(perikaryon or soma) (Figure 5) from which numerous processes (neurites) arise. This 
extensive branching is the most obvious sign of such specialization. 
  
University of Aveiro – Masters in Molecular Biomedicine 
Centre for Cell Biology 
2011 
 
18 
 
 
 
  
Figure 5. Schematic representation of a neuron (taken from Mescher, 2010). 
 
 The neurites that receive signals and transmit it to the cell body are called 
dendrites (Figure 5). Once in the cell body, a long neurite called axon (Figure 5) conducts 
those signals to the terminal arborization (Purves, 2004; Siegel and Sapru, 2005). The 
dendrites are morphologically distinguishable from axons by their irregular outline, by 
their diameter which decreases along their branching, by the acute angles between the 
branches, and by their ultrastructural characteristics. Dendrites are also the main 
sensorial region of the neurons, generating electric signals such as excitatory post-
synaptic potentials, inhibitory post-synaptic potentials or calcium action potentials. 
Although dendrites are generally a receptive zone, they can connect with other dendrites 
and act as a transmitter area by releasing neurotransmitters. Nissl granules, ribosomes, 
smooth endoplasmic reticulum, neurofilaments, microfilaments, microtubules, and 
mitochondria can be found in the dendrites. Usually, the axon rises from a small conical 
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elevation of the cell body called axon hillock. The axon has a smooth appearance and a 
uniform diameter along its extent. The plasma membrane of the axon is called axolemma, 
and its cytoplasm is called axoplasm, which contains mitochondria, microtubules and 
neurofilaments but lacks the Nissl substance or Golgi apparatus. The axon may be 
surrounded by a sheath called myelin. The presence or absence of such sheath makes the 
axon describable as myelinated or unmyelinated, respectively (Hammond, 2008). The cell 
body is the main site of synthesis of macromolecules since it is the compartment 
containing all the required organelles. Comparing with other cell types, the neuron differs 
primarily at the nuclear level. This is especially noticeable at the chromatin and nucleolus 
levels where chromatin is light and sparsely distributed, explaining why most neurons 
cannot divide, and the nucleolus is particularly large, indicating that there is a high level 
of protein synthesis in neurons (Hammond, 2008; Siegel and Sapru, 2005). At the 
cytoskeletal level, neurons and glia are also somewhat different from other cell types. 
Although many of the specialized fibrillar or tubular proteins that constitute the 
cytoskeleton are found in other cells, their peculiar organization in neurons is critical for 
the stability and function of neuronal processes and synaptic junctions. The filaments, 
tubules, vesicular motors and scaffolding proteins of neurons coordinate three vital 
events: (1) the growth of axons and dendrites, (2) the trafficking and appropriate 
positioning of membrane components, organelles, and vesicles, and (3) the active 
processes of exocytosis and endocytosis that underlie synaptic transmission (Hammond, 
2008; Purves, 2004). 
 Neurons establish specific contacts called synapses with other cells and therefore, 
the name of the mechanism by which neurons communicate with each other is called 
synaptic transmission (Hammond, 2008). Usually, synaptic transmission is conducted 
unidirectionally from a presynaptic neuron to a postsynaptic neuron, as shown in Figure 
6. These two neurons are separated by a 20-50 nm space called the synaptic cleft (Binder 
et al., 2008; Siegel and Sapru, 2005). In such cases we are most probably in presence of a 
chemical synapse, which is the most abundant type of synapse in the nervous system 
(Purves, 2004). Secretory organelles called synaptic vesicles are filled with small 
molecules, the neurotransmitters. These are the chemical signals secreted from the 
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presynaptic neuron, hence the name of this kind of synapse (Binder et al., 2008; Purves, 
2004). The mitochondria present in the cytoplasm of the presynaptic neuron produce 
ATP, which induces the accumulation of synaptic vesicles in the presynaptic neuron 
(Binder et al., 2008). 
  
 
Figure 6. Schematic diagram of a synapse (adapted from Morales, 2010). 
 
 The chemical synapse is initiated when an action potential invades the presynaptic 
neuron terminal, inducing depolarization of the presynaptic membrane thus causing the 
opening of present voltage-gated calcium channels. The opening of these channels result 
in a rapid influx of Ca
2+
 into the presynaptic terminal, evoking an increase in the 
intracellular Ca
2+ 
concentration. This factor is critical for triggering the fusion of the 
synaptic vesicles with the plasma membrane of the presynaptic neuron in a specialized 
region called the active site, resulting in the release of the neurotransmitters into the 
synaptic cleft (Binder et al., 2008; Hammond, 2008; Purves, 2004). Once released into the 
synaptic cleft, the neurotransmitters may bind to a variety of receptors: postsynaptic, 
presynaptic, glial, and in some synapses enzymes that degrade specific neurotransmitter 
molecules present in the synaptic cleft. In this way, information is transmitted from one 
neuron to another (Purves, 2004). Various neurons connect together forming circuits, 
which transmit and process information throughout the nervous system (Hammond, 
2008). Both pre- and post-synaptic membranes have specific proteins that permit their 
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distinction. For example, in the pre-synaptic terminal (Figure 7) we can find 
synaptophysin, synaptogyrin, SCAMPs (secretory carrier-associated membrane proteins) 
(Abraham et al., 2006), synapsins (Fdez and Hilfiker, 2006), SNARE (soluble NSF 
attachment protein receptor) complexes, SNAPs (synaptosomal-associated proteins), 
Munc13 (mammalian homologues of the C. elegans unc-13 gene), RIM (Rab3-interacting 
molecule) (Rizo and Rosenmund, 2008), and others, as shown in Figure 7. 
 
 
 
Figure 7. Schematic diagram of a pre-synaptic terminal showing localization of various presynaptic 
proteins. Intrinsic vesicle proteins [Synaptic vesicle protein 2 (SV2), synaptophysins, synaptotagmins, 
vesicle-associated membrane polypeptides (VAMPs), neurotransmitter transporters (NT transporters), 
synaptogyrins, proton pump], peripheral vesicle proteins [Rabs, cystine string proteins (CSPs), synapsins], 
synaptic plasma membrane proteins [calcium channels, synaptosome-associated protein of 25 kDa (SNAP-
25), syntaxin], and cytosolic proteins [SNAPs and n-Sec1 (Munc18)] are shown (taken from Staple et al., 
2000). 
 
 In the post-synaptic terminal (Figure 8), for example, we can find PSD-95 (post-
synaptic density-95), SAP90 (synapse-associated proteins 90), GKAP (guanylyl kinase-
associated protein), SHANK (SH3 [Src-homology region 3] domain and ankyrin repeat-
containing protein) (Kreienkamp, 2008), among others. PSD-95 is a member of the 
MAGUK (membrane-associated guanylyl kinase) family, which contains three PDZ (PSD-
95/Discs large/Zona occludens-1) domains, a SH3 domain or WW motif (two conserved 
tryptophan residues) and a region homologous to yeast guanylate kinase (GK) region (Cho 
et al., 1992; Kim and Sheng, 2004). NMDA (N-methyl-D-aspartate) receptors can be 
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coupled to metabotropic glutamate receptors and to the actin cytoskeleton through the 
actions of PSD-95, GKAP and SHANK. 
 
 
Figure 8. Schematic diagram showing the molecular constituents of the post-synaptic complex.  Many of 
the synaptic and trafficking proteins illustrated contain PDZ domains. Proteins that contain several PDZ 
domains, such as the MAGUK proteins, may therefore function as scaffold molecules to organize 
macromolecular protein complexes (taken from Scannevin and Huganir, 2000). 
 
 
1.4. Synaptosomes 
 
 The development of nerve terminal isolation techniques has granted the access to 
a powerful research tool, greatly enhancing the understanding of its functions (Dunkley et 
al., 2008). Firstly, the desired brain tissue is removed and isolated in an iso-osmotic 
solution with appropriate viscosity. Then, the tissue is homogenized with appropriate 
shear force, causing the release of the nerve terminals from their attached axons and glial 
cells, hence their referral as “pinched-off nerve endings”. Soon after rupture, most of the 
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lipid bilayers of the presynaptic membranes naturally reseal together, enclosing the nerve 
terminal contents (Bai and Witzmann, 2007; Whittaker, 1993). This includes the 
cytoplasm, synaptic vesicles, mitochondria and cytoskeleton. A minor portion of nerve 
terminals will be lost during homogenization, either because of their shape or size, or 
because their contents will leak before the membrane reseals. These resealed free nerve 
terminals with intact contents are designated synaptosomes (Figure 9) (Dunkley et al., 
2008; Whittaker, 1993). 
 
 
Figure 9. Electron microscopy of a synaptosome enriched fraction. Syn stands for synaptosomes. There are 
also present numerous synaptic vesicles (SV) and mitochondria (Mit). Scale bar is 1µm (adapted from 
Dunkley et al., 2008). 
 
 
1.4.1. The origin of synaptosomes 
 
 Synaptosomes (Whittaker et al., 1964) were first isolated by Hebb and Whittaker 
in 1957, receiving the designation of NEP, acronym for nerve-ending particle. The term 
‘synaptosome’ was first introduced in a paper dating 1964, as Whittaker thought that a 
“word more in accordance with normal scientific terminology was needed” (Whittaker, 
1993). At that time, Whittaker’s group was exploring the synaptosomal localization of 
several known neurotransmitters and their synthesizing enzymes. A second goal was to 
successfully subfractionate the lysed synaptosomes to obtain homogeneous fractions of 
synaptic vesicles and other synaptic components (Bai and Witzmann, 2007). As 
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synaptosomes were too small to be identified by light microscopy, investigators 
worldwide were skeptical about synaptosomal potential. An exception was George Gray, 
an electron microscopist who studied the synapse structure. The collaboration of 
Whittaker and Gray in 1960 culminated in the demystification of synaptosomes, as they 
were previously thought to be free synaptic vesicles (Harrison et al., 1988; Whittaker, 
1993). 
 
 
1.4.2. Morphological and functional characterization 
 
 The collaboration between Whittaker and Gray also resulted in the establishment 
of four morphological criteria for synaptosome identification: the presence within (1) a 
resealed plasma membrane of (2) at least one mitochondrion, (3) a local concentration of 
vesicles similar in size and number to those seen in situ and (4) the frequent presence of 
characteristically electron-dense membranes resembling postsynaptic membrane 
(Harrison et al., 1988; Whittaker, 1993). Synaptosomes have not only been characterized 
morphologically but also functionally: they produce ATP; they maintain membrane 
potentials and ion homeostasis which is granted by the presence of functional ion 
channels, carriers and receptors; their synaptic vesicles are still able to release and take 
up neurotransmitters; their membranes can be recycled by endocytosis; and they contain 
functional enzymes and proteins characteristic of nerve endings. Although synaptosomes 
maintain the viability of most synapse in situ functions, they lack the ability to synthesize 
new proteins (except within their mitochondria) and therefore, their repair capacity is 
limited to a few respiratory complex proteins (Harrison et al., 1988). 
 
 
1.5. Neurodegenerative diseases 
 
 Neurodegenerative diseases comprise a condition in which nerve cells are lost 
leading to either functional loss (ataxia) or sensory dysfunction (dementia). Mitochondrial 
dysfunctions, excitotoxicity and apoptosis have been reported as possible pathological 
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causes for neurodegenerative diseases such as Parkinson’s disease, multiple sclerosis, 
amyolotrophic lateral sclerosis and Alzheimer’s Disease (AD) (Mattson, 2004b). The 
neuronal loss is a relatively late event, usually following synaptic dysfunction and loss, 
neurite rectraction, and other apparent abnormalities, such as axonal transport defects. 
This observation suggests that programmed cell death may play at best only a secondary 
role in the neurodegenerative process (Galvan et al., 2006; Graham et al., 2006; Nikolaev 
et al., 2009; Saganich et al., 2006). Some studies suggest that deregulated calcium 
homeostasis is a great contributor to neurodegeneration, being implicated in 
neurodegenerative diseases like AD (Bezprozvanny and Mattson, 2008; Green and 
LaFerla, 2008; Mattson, 2004a, 2007; Selkoe, 2001a), Parkinson’s disease (Hallett and 
Standaert, 2004; Surmeier, 2007; Thomas and Beal, 2007), Huntington’s disease 
(Bezprozvanny, 2007; Fan and Raymond, 2007; Nakamura and Aminoff, 2007; 
Ramaswamy et al., 2007) and amyotrophic lateral sclerosis (Alexianu et al., 1994; 
Rowland and Shneider, 2001; Strong et al., 2005; von Lewinski and Keller, 2005). This 
calcium homeostasis disruption implies alterations of calcium buffer capacities, 
deregulation of calcium channel activities and/or excitotoxicity. In spite of being of 
growing importance in the neurodegenerative process, calcium homeostasis deregulation 
is rarely a direct causative agent (Bezprozvanny and Mattson, 2008; Wojda et al., 2008). 
 
 
1.6. Alzheimer’s Disease (AD) 
 
 AD is an irreversible and multifactorial neurodegenerative disorder that 
progressively destroys memory and cognitive skills (Ferri et al., 2005) and is the most 
common of dementia among the elderly. In the World Alzheimer Report of last year, 
Alzheimer’s disease International estimated that there are 35.6 million people living with 
the dementia worldwide. The situation is not different in Portugal, where it currently 
affects more than 90.000 people. This fact, allied to the evident constant aging 
population, is turning AD into an ever-increasing social burden (Neet and Thinakaran, 
2008). Both genetic and environmental factors can contribute to the AD etiology, as 5% of 
AD cases are caused by genetic factors, while 95% are sporadic. Age is the most 
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significant risk factor, with the chance of developing AD doubling every five years after 65 
(Kawas, 2003). Environmental factors speculated or implicated to contribute to 
development of AD include: level of education, history of head trauma, vascular changes, 
decreased levels of acetylcholine, and exposure to aluminum (Rogers, 1998). 
 It is often difficult to discern the precise onset of clinical AD but it frequently 
manifests as subtle and intermittent deficits in episodic memory. Following several 
months of gradually progressive impairment of first declarative and then also 
nondeclarative memory, other cognitive symptoms appear and slowly advance. After a 
distant period of years a profound dementia develops, affecting multiple cognitive and 
behavioral processes (Romanelli et al., 1990). The progressive cognitive and behavioral 
symptoms which characterize AD derive from profound functional and structural changes 
observed in neurons, their processes and synapses, and the microgliosis and astrocytosis 
which accompanies these changes (Selkoe, 2001b). In AD brains, there is widespread cell 
loss, in particular loss of cholinergic neurons, resulting in a decrease in acetylcholine. This 
loss explains, in part, the characteristic cholinergic dysfunction in AD (Bartus et al., 1982).  
 Progress in AD research has focused on three main aspects, understanding the 
APP and Abeta biology, developing novel therapeutical strategies based on disease-
modifying drugs and establishing methodologies for early diagnosis of AD. Obviously 
these three aspects are correlated, since the advances in APP and Abeta biology are 
important for developing efficient disease-modifying drugs and these drugs should be 
effective in patients in the earliest stages of AD. This at a stage prior to the generation of 
amyloid plaques and neurofibrillary tangles and consequently before neurodegeneration 
becomes too severe. The need for early diagnosis and prognosis of disease modifying 
drugs has created a need for biomarkers that reflect core elements of the disease 
process. Presently, the more efficient AD biomarkers are cerebrospinal fluid (CSF) 
biomarkers (Blennow and Hampel, 2003). Another tool that provides early diagnosis of 
AD is amyloid imaging, which relies on positron emission tomography studies with the 
amyloid tracer 
11
C-PiB (
11
C-labeled Pittsburgh compound B) (Mintun et al., 2006). 
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1.6.1. Neuropathological hallmarks  
 
 Post-mortem analysis of AD brain reveals four characteristic pathological 
hallmarks: synaptic and neuronal loss in distinct brain areas, including the neocortex and 
hippocampus, and the presence of amyloid plaques (AP) (Glenner and Wong, 1984) and 
neurofibrillary tangles (NFT) (Bancher et al., 1989). 
 Ramon y Cajal suggested, in 1928, that “dementia could result when synapses 
between neurons are weakened as a result of a more or less pathological condition, that 
is, when processes atrophy and no longer form contacts, when cortical mnemonic or 
association areas suffer partial disorganization” (Cajal, 1928). Analysis for pre and post-
synaptic markers by electron microscopy, biochemical and immunohistochemical analysis 
revealed a disproportional decrease of synapse number in relation to the loss of neuronal 
cell bodies (Bertoni-Freddari et al., 1996; Davies et al., 1987; DeKosky and Scheff, 1990), 
suggesting that pruning of synaptic endings may precede neuronal loss (Masliah et al., 
2001; Scheff et al., 2007; Scheff et al., 2006), hence explaining such phenomena in AD. 
 AP (Figure 10) are relatively insoluble extracellular deposits of 5-10 nm thick 
amyloid fibrils with a surrounding “halo” of dystrophic neurites, reactive astrocytes and 
activated microglia (Selkoe, 1999).  AP (Figure 10) are primarily composed of extracellular 
aggregates of Abeta, which normally occurs as a 40 – 42 residue peptide (Glenner and 
Wong, 1984). In vitro studies of Abeta aggregation kinetics demonstrated that Abeta 
monomers polymerize to form higher order aggregates in a concentration-dependent 
manner (Burdick et al., 1992). More recent studies, namely the seeded polymerization 
theory (Harper and Lansbury, 1997), suggest that polymerization of soluble Abeta 
monomers, which leads to AP formation, is nucleated by ‘bad seeds’ of oligomeric Abeta, 
possibly formed at the terminals of projections of brainstem neurons (Muresan and 
Muresan, 2008). Today, it is widely known that plaque formation is a common feature of 
the aging human brain that can occur in the absence of cognitive decline. Although, this 
accumulation of amyloid in the aging brain seems to result from failure to clear the 
amyloid peptides rather than from increased production (Dewachter et al., 2000). 
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Figure 10. Amyloid plaques in fixed tissue at autopsy (adapted from Huang et al., 2001). 
 
 NFTs (Figure 11) are intracellular neuronal lesions composed of insoluble, 
conformationally abnormal, hyperphosphorylated tau protein (Weingarten et al., 1975a). 
This is a consequence of excessive oxidative stress, caused by the activation of MAP 
kinase pathways. The activation of cell cycle regulators is also associated with NFT 
formation (Bryan et al., 2008).  
 
 
Figure 11. Neurofibrillary tangles in fixed tissue at autopsy (adapted from Huang et al., 2001). 
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1.6.2. Alzheimer’s amyloid precursor protein (APP) 
 
1.6.2.1. APP isoforms 
 
 The human APP gene, located on chromosome 21, was first identified in 1987 
(reviewed in Thinakaran and Koo, 2008). APP is an integral membrane protein with a large 
extracellular domain, a single transmembrane region and a short cytoplasmic domain. 
 There are three major APP isoforms, consisting of 695, 751, or 770 amino acids. 
The former is mainly expressed in neurons and is subjected to N- and O-glycosilation 
within its extracellular/luminal domain, while the two latter are predominant in non-
neuronal cells, especially glial cells in the brain (Li et al., 1999; Selkoe, 2001a). These 
isoforms are produced by alternative mRNA splicing, predominantly of exons 7, 8, and 15, 
of the APP gene. The APP isoforms are frequently divided into Kunitz-type protease 
inhibitor domain-containing isoform (KPI positive) or Kunitz-type protease inhibitor 
domain-lacking isoform (KPI negative). They are both generated by the alternative splicing 
of exon 7. Under normal conditions, the APP lacking the KPI and OX-2 regions (APP695) is 
the predominant form produced by neurons and neuronal cell lines. Also under normal 
conditions, the APP-KPI positive isoforms (APP751 and APP770) are the predominant forms 
expressed in non-neuronal cells, including glia, platelets, leukocytes, and many non-
neuronal cell lines (Golde et al., 1990; Mönning et al., 1992; Tanzi et al., 1988). Changes in 
the APP-KPI positive/APP-KPI negative ratio may occur under pathological conditions 
because it has been found that a greater proportion of the APP in AD brain consists of KPI 
positive isoforms (Ho et al., 1996; Li et al., 1999). 
 
 
1.6.2.2. APP processing 
 
 The Abeta peptide was originally defined as a pathogenic peptide associated with 
AD, but it is now known to be produced during normal APP processing (Haass et al., 
1992). APP metabolism is complex and can occur via several distinct pathways that have 
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not all been fully elucidated. In its simplest form, APP processing occurs via two 
pathways, α-secretase (non-amyloidogenic) and the β-secretase (amyloidogenic) (da Cruz 
e Silva and da Cruz e Silva, 2003; da Cruz e Silva et al., 2004), as shown in Figure 12. In the 
non-amyloidogenic pathway, α-secretase cleaves within the Abeta sequence of APP, 
generating soluble fragments of 100-130 kDa (sAPPα) and a 10 kDa membrane-associated 
carboxyl-terminal (CTFα) fragment (C83). This peptide can be further cleaved by the γ-
secretase complex, generating the p3 peptides, (Busciglio et al., 1993; Esch et al., 1990) 
and the intracellular domain of the Alzheimer’s amyloid precursor protein (AICD) (Sastre 
et al., 2001). The amyloidogenic pathway involves cleavage of APP at the amino terminus 
of Abeta by β-secretase, yielding sAPPβ and the CTFβ fragment (C99). Subsequent 
cleavage of CTFβ by γ-secretase complex yields the toxic Aβ1-40 (90%) and Aβ1-42/43 (10%) 
fragments (Busciglio et al., 1993; Haass et al., 1993) and also the AICD. Pathogenic 
mutations in APP at codon 717 lead to an increased proportion of Abeta1-42 being 
produced and secreted. Missense mutations in presenilin-1 (PSEN-1) are pathogenic in 
the majority of familial Alzheimer’s pedigrees, also leading to increased production of 
Abeta1-42 over Abeta1-40, which indicates the importance of PSEN-1 for the γ-secretase 
cleavages. 
 
 
Figure 12. APP proteolytical processing. 
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 Finally, these Abeta peptides are secreted by cells and can be detected in plasma 
and cerebrospinal fluid (Seubert et al., 1992). Though, it must be remembered that APP 
processing is a physiological process, meaning that both APP and Abeta have apparent 
physiological functions (reviewed in Pearson and Peers, 2006). 
 
 
1.6.2.3. APP and APP fragments functions 
 
 Although most of the literature on APP has focused on its potential pathological 
roles in the development of AD, in recent years there has been increasing interest in the 
physiological functions of APP (Ma et al., 2008). Since the discovery of APP, a number of 
physiological roles have been attributed to the molecule, but its actual functions remain 
unclear (Mattson, 1997). The discovery of the APP gene was followed by the identification 
of missense mutations associated with familial AD forms (early-onset). These mutations 
are found in and around the Abeta region of APP, and affect the production or 
aggregation properties of Abeta. APP, APLP1 and APLP2 are homologous type-1 
transmembrane proteins (Selkoe, 2001a) that are similarly post-translationally modified 
and processed, as well as having overlapping expression in brain (Bayer et al., 1999). APP 
has been implicated in diverse cellular processes involved in cell proliferation, cell 
survival, neuroprotection, enhancement of memory, neuronal excitability and regulation 
on synaptic plasticity (reviewed in Ma et al., 2008). It has been shown to stimulate neurite 
outgrowth. This is compatible with the up-regulation of APP expression during neuronal 
maturation. 
 APP-knockout studies revealed that they knockout subjects were lighter in body 
mass, and with age, there was weakness in the extremities. Brain examination showed 
gliosis, a rather non-specific astrocytic reaction. Synaptic markers were also reduced, and 
this correlated with deficits in learning and memory, as well as in synaptic plasticity. 
 Finally, Aplp2
-/-
/Aplp1
-/-
 and App
-/-
/Aplp2
-/-
 double mutants showed early postnatal 
lethality, possibly indicating that members of the APP gene family are essential genes that 
exhibit partial overlapping functions (Dawson et al., 1999; Zheng et al., 1995). 
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 Some studies have also indicated a role of sAPP in regulation of stem cells. On one 
hand, sAPPα induces the differentiation of neural stem cells into astrocytic lineage (Kwak 
et al., 2006). On the other, it also promotes neural stem cell proliferation (Caillé et al., 
2004).  Also, it was shown that the expression of sAPPα was sufficient to recover 
anatomical behavioral and electrophysiological abnormalities of APP-deficient mice 
(Rossjohn et al., 1999). APP appears to also promote cell adhesion, as it colocalizes with 
the integrins on the surface of axons and at sites of adhesion. It is now known that sAPPα 
has neuroprotective functions, induces synaptogenesis and neurite outgrowth and also 
contributes for synaptic plasticity. Both sAPPα and p3 are secreted by a variety of 
cultured cells and are found in human brain and CSF (Palmert et al., 1989; Schubert et al., 
1989a; Schubert et al., 1989b; Selkoe et al., 1988; Weidemann et al., 1989). 
 Similarly to APP, several lines of evidence indicate that Abeta may have a role in 
controlling synaptic activity. Some studies refer that evoked activity of hippocampal 
neurons by two bipolar electrodes in brain slices increased the production of Abeta 
primarily by increasing trafficking of APP towards β-secretase sites (Kamenetz et al., 
2003). This would promote Abeta formation, but also increase production of other 
fragments which may also modulate synaptic activity. At physiological expression levels of 
APP, this provided a negative feedback, since Abeta depresses synaptic activity. Without 
such depression, synaptic activity could become excessive, leading to excitotoxicity, 
suggesting that Abeta may serve to provide physiological control of activity, preventing 
excessive glutamate release (Kamenetz et al., 2003; Lesne et al., 2005; Steinbach et al., 
1998). Abeta absence tests in primary cultures caused specifically neuronal cell death. But 
interestingly, this event could be restored by addition of physiological levels (1-10 nm, 
which are the concentrations found in CSF) of Abeta, since it depresses synaptic activity 
(Pearson and Peers, 2006). This provides evidence for a role of Abeta in neuronal survival 
(Plant et al., 2003; Yu, 2003). 
 AICD can form a transcriptionally active complex together with two other 
molecules, Fe65 and Tip60. Although it was initially thought that AICD must enter the 
nucleus with Fe65, subsequent study showed that nuclear translocation of AICD is not 
required but may be indirect through Fe65 (Cao and Sudhof, 2004). 
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1.6.3. Tau 
 
 Tau consists in a family of six proteins derived from a single gene by alternative 
mRNA splicing (Himmler et al., 1989). The human brain tau isoforms range from 352 to 
441 amino acids. They differ in whether they cointain three (3R – R1, R3, and R4) or four 
(4R – R1, R2, R3, and R4) C-terminal repeats of 31 or 32 amino acids and by the presence 
of either one (N1) or two (N2) or no (N0) inserts of 29 amino acids in the N-terminal part 
(3R0N, 3R1N, 3R2N, 4R0N, 4R1N, 4R2N, see Figure 13). All of the six isoforms have been 
reported to be present in a hyperphosphorylated state in PHF (paired-helical filaments) 
(Grundke-Iqbal et al., 1986a; Grundke-Iqbal et al., 1986b; Lee et al., 1991). 
 
 
Figure 13. Tau isoforms. 
 One of the most important post-translational modifications that tau suffers is 
phosphorylation, because the degree of phosphorylation regulates its microtubules and 
tubulin-polymerizing activities (Lindwall and Cole, 1984). If tau is hyperphosphorylated it 
can dissociate from the microtubules and disrupt axonal transport (Busciglio et al., 1995). 
While in this form, it is the major protein subunit of the paired helical filaments (PHF) and 
straight filaments (SF) forming NFTs, neuropil threads, and plaque dystrophic neurites in 
AD (Grundke-Iqbal et al., 1986a; Grundke-Iqbal et al., 1986b). Tau is remarkably soluble 
and the major neuronal microtubule associated protein (Weingarten et al., 1975b). It 
normally functions to promote the assembly and stabilization of the microtubule 
cytoskeleton and is critical in the processes of neuronal outgrowth and axonal integrity 
(Ramsden et al., 2005; Rankin et al., 2007; Tatebayashi et al., 2004). 
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1.6.4. Protein phosphorylation 
 
 Reversible phosphorylation/dephosphorylation reactions (Figure 14) regulate 
protein activity and subcellular localization in many cellular processes. The equilibrium of 
the protein phosphorylation systems is also essential to maintain cellular health and 
vitality. Protein phosphatases (PP), enzymes counteracting protein kinases (PK) functions’, 
have been recognized as key coordinators of diverse biological events. Three main criteria 
are used to classify PPs: sequence homology, structure, and catalytic mechanism 
concerning substrate specificity. According to these features, PPs are divided into the 
three main groups: classical serine/threonine phosphatases, protein tyrosine 
phosphatases, and the aspartate based catalysis protein phosphatase (reviewed in 
Moorhead et al., 2007). Reverse protein phosphorylation involves the covalent 
modification of key substrate proteins by phosphoryl transfer (Pi), which in turn regulates 
their functional proteins. This post-translational modification can have profound effects 
on the activities and properties of various proteins. All protein phosphorylation systems 
have three components in common: (1) a substrate (phosphoprotein), either in the 
dephospho- or phospho-form, (2) a PK that catalyzes the transfer of phosphoryl from ATP 
to a specific hydroxylated amino acid of the substrate, and (3) a PP that catalyzes 
dephosphorylation of the phosphorylated substrate protein (Figure 14).  
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Figure 14. Schematic representation of reversible protein phosphorylation. Protein kinases transfer a 
phosphate group from ATP to a target protein (protein phosphorylation), while protein phosphatases 
catalyze the hydrolysis of the phosphate group from the target protein (protein dephosphorylation). 
 
 Phosphoproteins, PKs and PPs are all highly enriched in the synaptic region of 
nerve cells, indicating a major role for protein phosphorylation in synaptic transmission 
(Hemmings et al., 1986; Huganir and Greengard, 1987; Nairn et al., 1985). 
 Protein phosphorylation regulates several processes, like metabolism, 
contractility, membrane transport and secretion, transcription and translation of genes, 
cell division, fertilization and memory (reviewed in Cohen, 1989). Additionally, various 
diseases, like Alzheimer’s disease (AD), other neurodegenerative diseases and diabetes, 
are associated with abnormal phosphorylation of specific proteins. 
 
 
1.6.4.1. APP phosphorylation 
  
 APP is a phosphoprotein sustaining several phosphorylatable residues in its 
cytoplasmic (Gandy et al., 1988; Oltersdorf et al., 1990) and luminal regions (Hung and 
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Selkoe, 1994; Knops et al., 1993). More precisely, APP has ten phosphorylatable residues: 
two are located in its ectodomain and the other eight in the APP cytoplasmic domain. 
In addition, APP was found to be phosphorylated in AD patients (Lee et al., 2003) but only 
some of the responsible kinases have been identified (Friedhoff et al., 2000). Ectodomain 
phosphorylation was reported to occur at Ser198 and Ser206 of APP (numbering for 
APP695) (Walter et al., 1997), which represent phosphorylation sites for casein kinase (CK)-
2 and CK-1, respectively (Walter et al., 2000). Other residues (Tyr653, Ser675, and Thr686) 
also have been reported as potentially phosphorylatable (Lee et al., 2003), but have 
received little attention and so, their putative kinases are still not known. Thr654 and 
Ser655 were also been reported to be phosphorylated in rat brain (Oishi et al., 1997). 
Both have been reported to be phosphorylated by calcium/calmodulin-dependent protein 
kinase II (CaMKII) (Gandy et al., 1988), but the latter was also reported to be 
phosphorylated by protein kinase C (PKC) (Gandy et al., 1988). Tyr682 was shown to be 
phosphorylated in vitro by Tyrosine kinases, TrkA and c-Abl (Tarr et al., 2002). One 
additional residue, Tyr687 was found to be phosphorylated (Lee et al., 2003), though its 
kinase has not been identified yet. 
The specific hyperphosphorylation at Thr668 plays a pivotal role in APP processing and is 
highly relevant to AD. The kinases responsible for Thr668 phosphorylation are JNK, CDK5, 
and GSK-3β but the conditions and the precise role of these kinases in APP metabolism 
have still to be elucidated (reviewed in Muresan and Muresan, 2007). JNK is a key 
pathway in excitotoxicity, Abeta toxicity and AD pathology and modulates APP 
phosphorylation in differentiated neurons. CDK5 also has an important role in 
excitotoxicity as well as AD pathogenesis. Finally, GSK-3β is of particular relevance to 
neurological disorders since it phosphorylates APP at Thr668, as well as tau and PSEN-1. 
 The mechanism of APP phosphorylation is only partially characterized. It was 
thought that the primary site of APP phosphorylation in AD neurons was the endosome, 
but recent studies indicate that phosphorylated APP (p-APP) is recruited to Golgi-derived 
vesicles and is transported by kinesin-1 into neurites (Lee et al., 2003; Muresan and 
Muresan, 2005). 
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1.6.4.2. Tau phosphorylation 
 
 As far as the recent knowledge concerns, it is known that tau aggregation is 
accompanied by extensive phosphorylation, mainly by CDK5 and GSK3β. The reversible 
protein phosphorylation is important to regulate neuronal functions. Tau can be 
phosphorylated in approximately 30 serine/threonine residues, and its phosphorylated-
dephosphorylated degree is in homeostasis in normal adult brains, containing at least two 
to three phosphate groups per molecule. However, PHF-tau contains eight to ten 
phosphate groups per molecule in AD brains (Köpke et al., 1993). Also in AD brains, the 
activities of PP2A and PP1 are compromised by 20% (Gong et al., 1993). PP2A regulates 
the phosphorylation of tau, accounts for over 70% of tau phosphatase activity, and 
regulates the activity of several tau kinases in brain (Liu et al., 2005). In vitro inhibition of 
PP2A results in abnormal hyperphosphorylation of tau at several of the same sites as in 
AD, not only directly by a decrease in dephosphorylation but also indirectly by promoting 
the activities of several tau kinases (Li et al., 2004; Pei et al., 2003). This suggests that the 
abnormal tau hyperphosphorylation could be the result of upregulation of tau kinases or 
downregulation of tau phosphatases in AD brains (Huang and Jiang, 2009).  
 Two different types of kinases can phosphorylate the 30 above mentioned 
phosphorylation sites. One is the proline directed kinases, like MAP kinase, CDCK2, CDK5, 
GSK-3, JUN/SAPK and p38. The other is non-proline directed kinases, including PKA, PKC, 
CaMKII and CK-I/IICKII. The hyperphosphorylated tau is more resistant to proteolytic 
cleavage by different tau proteases in vivo, and it could be accumulated in neurons, 
thereby exerting its toxic effect. 
 In addition to PP2, which possesses three sub-classifications (PP2A, PP2B and 
PP2C) accordingly to its dependence on divalent metal ions, there is PP1 and PP5. Among 
these phosphatases and in addition to PP2A, PP2B downregulation also induces tau 
hyperphosphorylation (Gong et al., 2005; Rankin et al., 2007; Sato et al., 2002; Shimura et 
al., 2004). Tau phosphorylation events are probably sequential during the development of 
tau filaments. As suggested in Figure 15 below, during early pathological stages 
(pretangle) the predominant phosphorylation events are probably those decreasing the 
ability of tau to bind microtubules rather than those that increase its ability to self-
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associate. Most likely, this is caused by an imbalance in protein kinase and phosphatase 
(Ptase) activity. 
 
 
Figure 15. Possible mechanism of tau filament production (taken from Johnson and Stoothoff, 2004). 
 
 Labeling of AD brain neurons with antibodies directed to p-Thr231 and p-Ser262, 
followed by phosphorylation of both these sites, significantly decreases interactions of 
tau with microtubules. Afterward, tau can be cleaved by caspases and/or phosphorylated 
at additional sites such as Ser422 and Ser396/404, increasing the susceptibility of tau to 
oligomerize and eventually form filaments. The exact role that tau oligomers and 
filaments play in the cell dysfunction/death process has not yet been clearly defined 
(reviewed in Johnson and Stoothoff, 2004). 
 In AD tau becomes hyperphosphorylated (Grundke-Iqbal et al., 1986b), although 
the mechanism by which tau exerts its neuronal toxicity is not clear yet (Ballatore et al., 
2007; Stoothoff and Johnson, 2005). Recent studies (Amadoro et al., 2011) corroborate 
this fact, since it was found that an increase of tau phosphorylation at two relevant AD 
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epitopes (pSer262 and pThr231) completely overlapped the temporal appearance of 
Abeta peptides. Moreover in the same study, a preliminary set of experiments performed 
in hippocampal neurons undergoing cell death upon neuronal growth factor withdrawal 
shown tau hyperphosphorylation in the same epitopes, which is exclusively detected in 
PHF-tau at early AD stage. It has been suggested that hyperphosphorylated tau misfolds, 
detaches from microtubules and clogs axonal transport by interfering with motor 
proteins, thus altering the microtubule stability and normal neuronal functions. In 
addition, cytosolic abnormally hyperphosphorylated tau sequesters normal tau and other 
two microtubule associated proteins (MAP1A/MAP1B and MAP2), further contributing to 
microtubules disassembly and neuronal damage (reviewed in Amadoro et al., 2011).  
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2. AIMS OF THE DISSERTATION 
 
 
 AD exhibits two neuropathological hallmarks, amyloid deposits as amyloid plaques 
(APs) and neurofibrillary tangles (NFTs), which consist mainly of hyperphosphorylated tau 
protein. Both APs and NFTs contribute to neurodegeneration but the mechanisms 
whereby Abeta induces synaptic dysfunction remain unclear. Furthermore the clear 
relationship between APs and NFTs is unknown. However, consensus is beginning to 
develop that the formation of these two AD hallmarks are related and not independent 
and that Abeta and APP can effectively influence the formation of tau tangles in areas of 
the brain known to be affected with AD (Gotz et al., 2007; Lewis et al., 2001). Abeta is 
tipically produced during normal cellular APP metabolism and triggers several responses. 
It has acute, multiple negative effects on acetylcholine synthesis and release without 
inducing neurotoxicity, suggesting that Abeta appears to have a neuromodulatory role on 
central cholinergic functions that are central to AD. Long-term exposure to micromolar 
Abeta peptide concentrations induces cholinergic cell toxicity via tau 
hyperphosphorylation. Therefore we are particularly interested in determining the effect 
of Abeta on APP and tau phosphorylation using a specific model system (synaptosomes) 
that would mimic what the synapse. Synaptosomes are actually recognized as important 
model systems for neuroscience research since the integrity of nerve terminals is 
maintained and they are functionally active.  
 
 
The specific aims of this dissertation are: 
1. Preparation of synaptosome-enriched fractions; 
2. Establishing Abeta effects on synaptosomal viability; 
3. Determining Abeta effects on APP and tau phosphorylation. 
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3. MATERIALS AND METHODS 
 
3.1. Antibodies 
 
 The primary antibodies used are summarized in Table 1. Synaptophysin 1 antibody 
(Synaptic Systems) was used to detect synaptophysin, a pre-synaptic marker. PSD-95 
antibody (Millipore) detects the post-synaptic density, an electron dense structure just 
beneath the post-synaptic membrane and hence, was used as a post-synaptic marker. To 
detect holo-APP the 22C11 antibody (Chemicon) was used. Anti-C-Terminal (Zymed) was 
also used to detect holo-APP. To detect APP phosphorylated at Thr668 the polyclonal 
anti-p-APP (Thr668 antibody) (Cell Signaling Technology) was used. Tau5 antibody 
(Millipore) was used to detect total-tau. To detect tau phosphorylated at Ser202 and 
Thr205 the AT8 antibody (Thermo Scientific) was used. The p-tau antibody (Ser262) 
(Santa Cruz) was used to detect phosphorylated tau at the Ser262 residue. ATP Synthase 
α (BD Biosciences) was the antibody used as mitochondrial marker. The dilutions of each 
antibody are also indicated in Table 1. As the primary antibodies were prepared from 
different sources, different secondary antibodies were used: anti-mouse and anti-rabbit 
horseradish peroxidase-linked antibodies (GE Healthcare). 
 
Table 1. Primary antibodies used. The antibodies dilution, detection method and expected band size are 
indicated. 
Antibody Dilution Antibody 
Detection 
Method 
Expected 
Band 
Size(kDa) 
Synaptophysin 1 1:5000 Mouse (Monoclonal) ECL 37 
PSD-95 1:500 Mouse (Monoclonal) ECL 95 
ATP Synthase α 1:10000 Mouse (Monoclonal) ECL 55 
22C11 (holo-APP, N-Term.) 1:150 Mouse (Monoclonal) ECL 110-130 
C-Terminal (holo-APP, C-Term.) 1:500 Rabbit (Polyclonal) ECL Plus 110-130 
p-APP Thr668 1:1000 Rabbit (Polyclonal) ECL Plus 100-140 
Tau 5 (total-tau) 1:500 Mouse (Monoclonal) ECL 45-68 
p-tau Ser262 1:500 Rabbit (Polyclonal) ECL Plus 46-68 
AT8 (p-tau Ser202, Thr205) 1:500 Mouse (Monoclonal) ECL Plus 50 
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3.2. Brain dissection 
 
 Wistar rats (9-12 weeks) were obtained from Harlan Interfaune Ibérica, SL. 
Animals were maintained under controlled environment (26 
o
C and 12 hour light cycle 
with food and water ad libitum). They were handled according to the European Union 
guidelines (86/609/EEC). Animals were sacrificed by cervical stretching followed by 
decapitation. The two cortex and the two hippocampi from each rat were dissected out 
on ice. 
 
 
3.3. Synaptosome isolation 
 
 Synaptosomes were prepared from both rat cortex (cortical synaptosomes) and 
hippocampus (hippocampal synaptosomes). The two cortex and the two hippocampi from 
one animal were weighted and added to 10x homogenizing buffer (0,32 M sacarose, 50 
mM Tris, 2 mM EGTA, 1 mM DTT, pH 7.6). Tissues were then homogenized at 4
o
C with a 
Potter-Elvehjem tissue homogenizer with 10-15 strokes at 650-750 rpm. Before 
centrifugation an aliquot of homogenized tissue was collected. The tubes were then 
centrifuged at 3.000 g for 10 minutes at 4
o
C. The pellet (P1) was discarded and the 
supernatants (S1) were collected and centrifuged at 14.000 g for 20 minutes at 4
o
C. The 
supernatants (S2) were collected and stored at 4
o
C to be further analyzed. The pellet (P2) 
was ressuspended in Percoll® 45% (v/v), prepared in Krebs buffer (140 mM NaCl, 5 mM 
KCl, 25 mM HEPES, 1 mM EDTA, 10 mM glucose, pH 7.4) and centrifuged at 14.000 g for 2 
minutes at 4
o
C. The top layer (synaptosomal fraction) was collected with a Pasteur 
pipette and further washed in 1 mL Krebs buffer and centrifuged at 14.000 g for another 2 
minutes at 4
o
C. This washing step was repeated twice. The enriched synaptosome 
fractions were used for the following assays. 
 Samples from the various fractions were collected to be further analyzed. These 
included homogenates (H), the supernatant from the second centrifugation (S2), the 
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supernatants from the washing steps (Sn) and enriched synaptosomal fractions (Syn). All 
these samples where precipitated with acetone. 
 
 
3.4. Acetone protein precipitation 
 
 The acetone protein precipitation method is based in the dielectric constant (DC) 
of a solution. Solvent molecules with large DCs (water) can stabilize the interaction 
between themselves and protein molecules, favoring the dissolution of protein. 
Conversely, organic solvents with small DCs (acetone, methanol) prevent the dispersion 
of protein molecules in the media. These solvents lower the solubility of the proteins, 
inducing precipitation. To precipitate the proteins in the test tubes acetone was used. 
Acetone was previously cooled at -20 
o
C. Since the initial volume of sample in the tubes 
was known, we added 4x the volume of the sample in acetone at -20 
o
C to each tube. All 
samples were vortexed and incubated overnight at -20
 o
C. Next day, the samples were 
centrifuged at 14.000 g for 10 minutes and the supernatant was discarded. The pellets 
were dried for about 30 minutes at room temperature and then resuspended with boiling 
1% SDS. After homogenization these samples were boiled for 10 minutes, sonicated, and 
the protein content determined using BCA assay (as described below). 
 
 
3.5. Abeta synaptosomal treatment 
 
 Enriched synaptosome fractions were used to perform in vitro assays, where we 
evaluated the effect of Abeta1-42 treatment on APP and tau phosphorylation. With this 
proposal we incubated the enriched-synaptosomal fractions with three different Abeta1-42 
concentrations: 0,25 μM, 0,5 μM and 2 μM. To determine the test validity we added an 
extra condition (positive control), which consisted in scrambled Abeta1-42 at 2 μM. The 
Abeta1-42 stocks were previously prepared and used at 100 μM. After Abeta1-42 addition, 
the synaptosomes were incubated at 37
 o
C for three hours. After that period, one aliquot 
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of each sample was collected for further determination of protein content and loading 
buffer (LB) was added to each tube. The samples were then boiled for 10 minutes and 
subsequently analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). 
 
 
3.6. MTT assay 
 
 MTT assay is a cell viability colorimetric assay that measures the reduction of the 
yellow compound 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) by 
succinate dehydrogenase. MTT enters the cells and passes into the mitochondria where it 
is reduced to an insoluble, colored (dark purple) formazan product. The cells are then 
solubilized with an organic solvent (in this case, isopropanol), releasing formazan, which is 
then spectrophotometrically measured. Since MTT reduction can only occur in 
metabolically active cells, the level of formazan formation is a measure of cell viability. 
 For this assay enriched synaptosomal fractions were used. With this assay we 
evaluated the effect of Abeta1-42 treatment on synaptosomal viability. The same Abeta1-42 
stock was used as described above (Abeta1-42 0,25 μM, 0,5 μM and 2 μM) and the 
enriched-synaptosomal fractions were then incubated for 2 hours at 37
o
C. At the end of 
the 2
nd
 hour, we added MTT for a final concentration of 0,5 mg/mL to each tube and the 
incubation proceeded for 1 more hour at the same temperature. After incubation, we 
added HCl/Isopropanol 40 mM to each tube in a 1:1 proportion to MTT. The formazan 
crystals were ressuspended and the tubes were centrifuged at 13.000 g for 2 minutes. 
The supernatants were then transferred for spectrophotometer readable cuvetes and 
read at 570 nm. 
 
 
3.7. BCA protein quantification assay 
 
 Protein determination was performed using the bicinchoninic acid (BCA) protein 
assay (Pierce). This method is a detergent-compatible formulation based on BCA for the 
colorimetric detection and quantification of total protein. It combines the reduction of 
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Cu
+2
 to Cu
+
 by protein in an alkaline medium (biuret reaction) with the highly sensitive 
and selective colorimetric detection of Cu
+
, using a reagent containing the BCA. The 
purple-colored reaction product of this assay is formed by the chelation of two molecules 
of BCA with one Cu
+
 ion. This water-soluble complex exhibits its peak absorbance at 562 
nm that is nearly linear with increasing protein concentrations over a broad working 
range of 20 to 2.000 μg/mL. 
 The standards (final volume = 50 μL) were prepared in duplicate as described in 
Table 2. After standards and samples preparation, the working reagent (WR) was also 
prepared. 
 
Table 2. Preparation of the BCA standards. 
Standards BSA (µL) 10% SDS (µL) H2O (µL) Protein mass (µg) 
P0 0 5 45 0 
P1 1 5 44 2 
P2 2 5 43 4 
P3 5 5 40 10 
P4 10 5 35 20 
P5 20 5 25 40 
P6 40 5 5 80 
 
 To prepare the WR 50 parts of BCA reagent A was mixed with 1 part of BCA 
reagent B. After preparation, the WR was added to the samples and standards, and 
incubated at 37
o
C for 30 minutes. After that period of time, the tubes were left at room 
temperature for 3 minutes and then the absorbances were read at 562 nm. A standard 
curve was prepared by plotting the optical density (OD) value for each standard versus its 
concentration. This curve allowed the estimation of the protein concentration of each 
sample. 
 
 
3.8. SDS-Polyacrylamide gel electrophoresis 
 
 Samples were run in a SDS-polyacrylamide gel electrophoresis (SDS-PAGE). This is 
a method where proteins are resolved in a semi-solid matrix, the polyacrylamide gel, on 
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the basis of their molecular weight. This is possible by adding SDS, an anionic detergent 
that denatures proteins by wrapping around the polypeptide backbone. The denaturation 
procedure negatively charges the molecules to the same degree in proportion to its 
length. Under these conditions, the mobility of the molecules is relative to its size: light 
molecules migrate faster in the gel, while the migration of heavy molecules is slower. 
 Samples were prepared and 4x Loading Buffer (LB) was added to each tube. After 
the addition of LB, the samples were boiled and loaded into a 5% to 20% gradient gel. 
Gradient gels were used as they can separate a greater range of protein Mr (relative 
molecular mass) values, even if the Mr values from different proteins are very close. Gels 
were then run at 90 mA for about 3 hours. 
 
 
3.9. Immunoblotting 
 
 The immunoblotting technique, also known as Western blot, is a technique used 
to identify and locate proteins based on their ability to bind specific antibodies. It 
provides information about the presence, relative molecular weight and expression 
amount of a protein. Western blot is highly dependent on the quality of the antibody 
used to probe the protein of interest, and on the specificity of the antibody to the same 
protein. Blotting assumes the transference of DNA, RNA or proteins from an 
electrophoresis gel to a solid support. In our experimental system, proteins were 
transferred to nitrocellulose membranes overnight at 200 mA. 
 The first step in immunoblotting is rehydration of the membrane using 1x TBS. The 
next step is blockade of non-specific bindings of the primary antibody. This is achieved by 
incubating the membranes with 5% non-fat dry milk in 1x TBS-T (blocking solution). Then, 
the membranes were incubated with primary antibody (diluted in 3% non-fat dry milk in 
wash buffer) overnight. After incubation with the primary antibody the membranes are 
washed 3 times for 10 minutes in wash buffer. A secondary antibody conjugated with 
horseradish peroxidase is then added to bind the primary antibody and incubate for 2 
hours. The secondary antibody is always used at a 1:5000 dilution and is diluted in the 
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same solution as the primary. After the secondary antibody incubation the membranes 
are again washed 3 times for 10 minutes with 1x TBS-T.  
 An exception for this procedure is the Tau5 primary antibody that requires 
overnight blocking with a different solution – 5% BSA in 1x TBS-T. This different blocking 
solution is the same used to dilute the primary and secondary antibodies. 
 For detection, either enhanced chemiluminescence detection (ECL) or ECL Plus kits 
(Amersham) were used. ECL incubates in the membrane at room temperature for 1 
minute, while ECL Plus incubates at the same conditions for 5 minutes. Excess detection 
reagent is drained off the membrane. The blot is then placed in an X-ray film cassette 
with a sheet of film on top of it. Subsequently, the cassette is closed for 5 minutes and 
then developed with developer solution. After development the film is fixed and dried for 
subsequent quantification. 
 
 
3.10. Quantification and statistical analysis 
 
 Immunoblots were scanned and quantified using the Quantity One densitometry 
software (Bio-Rad). Data are expressed as means ± SEM of triplicate determinations, from 
at least three independent experiments. 
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4. RESULTS 
 
4.1. Isolation of synaptosome-enriched fractions 
 
4.1.1. Cortical fractions 
 
 In order to evaluate the effect of Abeta1-42 treatment on APP and tau 
phosphorylation we used enriched synaptosomal fractions as a model, mimicking what is 
happening at the synapse. Therefore, we set up all the methodology needed to isolate 
enriched cortical and hippocampal synaptosomal fractions. Briefly, cortex and 
hippocampus homogenates from rat brain were subjected to consecutive centrifugations 
and fractionation by Percoll® gradient. Four aliquots were taken during the isolation 
procedure, as follows: homogenate (H), supernatant from the second centrifugation (S2), 
inferior fraction after Percoll® ressuspension and supernatants from washing steps (Sn) 
and lastly, the synaptosomal fraction (Syn). The homogenate aliquot was used as a 
control to estimate the expression of the various subcellular markers used. After isolation 
and determination of the protein content, the samples were subjected to SDS-PAGE and 
analysed by immunoblotting using specific antibodies against the protein of interest. 
Synaptosomal fractions are enriched in pre-synaptic and post-synaptic proteins and also, 
due to their functional viability, are abundant in mitochondria (Whittaker, 1993). 
Therefore, we tested if our synaptosomal fractions were enriched in pre-synaptic protein 
(synaptophysin), post-synaptic protein (PSD-95) and mitochondria (ATP-synthase α). 
 The results obtained for cortical synaptosomes isolation are shown in Figure 16. As 
expected, immunoblotting analysis showed a marked increase of synaptophysin and PSD-
95 levels in the synaptosomal fraction, when compared with the other isolation fractions 
(Figure 16, Panels A and B). In addition, the high levels of ATP-synthase α indicated the 
presence of abundant mitochondria in the synaptosomal fraction (Figure 16, Panel C). 
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Figure 16. Analysis of several synaptosomal markers in different cortical fractions. (A) Relative levels of 
the pre-synaptic marker synaptophysin. (B) Relative levels of the post-synaptic marker PSD-95. (C) Relative 
levels of the mitochondrial marker ATP-synthase α (ATP-S α). H: homogenate, S2: supernatant from the 
second centrifugation, Sn: inferior fraction after Percoll® ressuspension and supernatants from washing 
steps, Syn: synaptosomal fraction. Values shown represent percentage of the control (homogenate). Data 
were obtained from two experiments (n = 2). 
 
 The homogenate fraction gives a clear idea of the levels of Synaptophysin, PSD-95 
and ATP-synthase α in the beginning of synaptosome isolation. The other three fractions 
  
University of Aveiro – Masters in Molecular Biomedicine 
Centre for Cell Biology 
2011 
 
50 
 
 
 
(S2, Sn, and Syn) reflect what happened during the isolation procedure. The homogenate 
fraction has the highest synaptophysin levels (Figure 16, Panel A), concordantly with the 
expected high levels of pre-synaptic membranes. Subsequent centrifugations and Percoll® 
gradient fractionation contributed to synaptosome isolation. Such is demonstrated by the 
accentuated decrease of synaptophysin levels from the H fraction to the S2 fraction, and 
by a concomitant increase of Sn and Syn fractions. These results suggest the enrichment 
of pre-synaptic membranes in the Syn fraction. The same behavior was observed for PSD-
95, indicating an enrichment of post-synaptic membranes of the synaptosomal fraction. 
ATP-synthase α levels (Figure 16, Panel C) were unexpectedly high in Sn and Syn fractions, 
indicating the presence of abundant mitochondria in both fractions. 
 
 
4.1.2. Hippocampal fractions 
 
 Identical methodology was used to isolate hippocampal synaptosome-enriched 
fractions and identical fractions were collected. However, the homogenate fraction was 
not collected due to reduced yield obtained during synaptosome isolation from the 
hippocampus. The results obtained for hippocampal synaptosome-enriched fractions are 
presented in Figure 17, and have a very similar pattern to that observed in synaptosome 
isolation from the cortex. 
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Figure 17. Analysis of several synaptosomal markers in different hippocampal fractions. (A) Relative levels 
of the pre-synaptic marker synaptophysin. (B) Relative levels of the post-synaptic marker PSD-95. (C) 
Relative levels of the mitochondrial marker ATP-synthase α (ATP-S α). S2: supernatant from the second 
centrifugation, Sn: inferior fraction after Percoll® ressuspension and supernatants from washing steps, Syn: 
synaptosomal fraction. Values shown represent percentage of the control (synaptosomal fraction). Data 
were obtained from two experiments (n = 2). 
 
 We observed an increase from the S2 to the Syn fractions in the levels of pre- and 
post-synaptic markers during the isolation procedure. In addition, Figure 17 Panel C also 
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demonstrated an increase of ATP-synthase α levels, evidencing a mitochondria increase in 
the synaptosomal fraction. 
 Having established that our cortical and hippocampal synaptosome-enriched 
fractions were enriched in pre- and post-synaptic proteins, it is reasonable to assume that 
they were isolated cortical and hippocampal synaptosome-enriched fractions. These were 
subsequently used to test the effect of Abeta1-42 treatment on synaptosomal viability and 
also on APP and tau phosphorylation. 
 
 
4.2. Effect of Abeta treatment on synaptosome viability 
 
4.2.1. Cortical synaptosome-enriched fractions 
 
 
 To determine the effect of Abeta1-42 on synaptosome viability, synaptosome-
enriched fractions were used and subjected to the MTT reduction test as mentioned in 
Section 3.6. Briefly, the synaptosome-enriched fractions were incubated with increasing 
concentrations of Abeta1-42 peptide (0,25 μM, 0,5 μM and 2 μM) and with scrambled 
Abeta1-42 for a period of three hours. During the last hour of Abeta1-42 incubation, MTT 
was added to a final concentration of 0,5 mg/mL, and one hour later the formazan 
crystals were solubilized with a HCl/Isopropanol solution and quantified by 
spectrophotometry. Values are expressed as a percentage of optical density of control 
synaptosomes. The MTT results (Figure 18), revealed that when cortical synaptosome-
enriched fractions were treated with different Abeta1-42 concentrations, a decrease in 
synaptosome viability was observed, which was dose-dependent. 
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Figure 18. Measurement of cortical synaptosome-enriched fractions viability after their treatment with 
Abeta1-42 peptide using the MTT reduction assay. Data shows the viability for cortical synaptosomes. Values 
are expressed as a percentage of the control. Data were obtained from three experiments (n = 3). 
 
 Therefore, an Abeta1-42 concentration of 0,25 μM did not affect synaptosomal 
viability, while the concentrations of 0,5 μM and 2 μM decreased viability by 
approximately 10% and 20%, respectively. Scrambled Abeta1-42 (2 μM) was also used and 
produced an increase on synaptosome viability. 
 
 
4.2.2. Hippocampal synaptosome-enriched fractions 
 
 For the hippocampus, the same procedure was used and hippocampal 
synaptosome-enriched fractions were incubated with different Abeta1-42 concentrations 
and with scrambled Abeta1-42 (2 μM). The MTT assay was carried out as mentioned above 
(for cortical synaptosome-enriched fractions) and the results are presented in Figure 19. 
The treatment of hippocampal synaptosome-enriched fractions (Figure 19) with Abeta1-42 
also resulted in a decrease in synaptosomal viability, with the highest decrease observed 
at the lower Abeta1-42 concentrations. 
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Figure 19. Measurement of hippocampal synaptosome-enriched fractions viability after their treatment 
with Abeta1-42 peptide using the MTT reduction assay. Data shows the viability for the hippocampus. 
Values shown represent percentage of control. Data were obtained from three experiments (n = 2). 
 
 With 0,5 μM and 2 μM of Abeta1-42 the viability decreased by approximately 20% 
and 10%, respectively. Scrambled Abeta1-42 seemed to slightly reduce the viability of 
hippocampal synaptosome-enriched fractions. 
 Data presented so far indicated that when both cortical and hippocampal 
synaptosome-enriched fractions are treated with increasing Abeta1-42 concentrations 
their viability did not dramatically changed. Therefore, we tested the effect of those 
Abeta1-42 concentrations on APP and tau phosphorylation. 
 
 
4.3. Effect of Abeta treatment on APP and tau 
phosphorylation 
 
4.3.1. Cortical synaptosome-enriched fractions 
 
 Cortical synaptosome-enriched fractions were treated with Abeta1-42 peptide as 
described in Section 3.5. Briefly, Abeta1-42 at different concentrations (0,25 μM, 0,5 μM 
and 2 μM) was added to the cortical synaptosome-enriched fractions. A control was also 
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included, which consisted of scrambled Abeta1-42 at a concentration of 2 μM. Three hours 
after Abeta1-42 incubation the cortical synaptosome-enriched fractions were harvested 
and analysed by SDS-PAGE and immunoblotting, using specific antibodies. 
 
 
4.3.1.1. APP phosphorylation 
 
 The effects of Abeta1-42 on APP phosphorylation are shown in Figure 20. The 
detection of holo-APP was achieved by using 22C11 antibody which recognizes the N-
terminal of APP and C-Terminal antibody, which detects the C-terminus of APP. The p-APP 
(Thr668) antibody was used to detect the APP phosphorylated at this residue. The levels 
of holo-APP in cortical synaptosome-enriched fractions, when treated with different 
Abeta1-42 concentrations are presented in Figure 20 Panels A and B. Analysis of these 
results demonstrates that the levels of holo-APP (C-Terminal) did not change with 
increasing Abeta1-42 concentrations (Figure 20 Panel B). However, the APP 
phosphorylation at Thr668 residue increases with Abeta1-42 treatment, being more 
evident with lower Abeta1-42 concentrations (0,25 and 0,5 μM) (Figure 20, Panel C). The p-
APP (Thr668)/holo-APP (C-Terminal) ratio was calculated (Figure 20, Panel D) and 
unequivocally shows that when cortical synaptosome-enriched fractions were treated 
with different Abeta1-42 concentrations, an increase on APP phosphorylation at Thr668 
residue was observed, being higher with the lower Abeta1-42 concentrations. 
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Figure 20. Relative levels of holo-APP and p-APP (Thr668) on cortical synaptosome-enriched fractions. (A) 
holo-APP detected with 22C11 antibody. (B) holo-APP detected with C-Terminal antibody. (C) p-APP 
(Thr668) detected using a phosphorylation-specific antibody against Thr668. (D) p-APP (Thr668)/holo-APP 
(C-Terminal) ratio. Values shown represent percentage of the control. Data were obtained from three 
independent experiments (n = 3). 
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4.3.1.2. Tau phosphorylation 
 
 The effects of Abeta1-42 treatment on tau phosphorylation were also monitored 
and are presented in Figure 21. The detection of total tau was performed using the tau5 
antibody. The AT8 and p-tau (Ser262) antibodies were used to detect tau phosphorylation 
at Ser202 and Thr205 (analyzed together) and Ser262 residues, respectively. The levels of 
total tau in cortical synaptosome-enriched fractions upon Abeta1-42 treatment did not 
dramatically change. Only a slight decrease is observed with the concentrations tested 
(Figure 21, Panel A). The Abeta1-42 treatment of synaptosome-enriched fractions 
produced a slight increase in tau phosphorylation at Ser262 residue at all concentrations 
tested (Figure 21 Panel B). However, tau phosphorylation at Ser 202 and Thr205 increased 
at lower Abeta1-42 concentrations (0,25 and 0,5 µM) and did not change with higher 
Abeta1-42 concentrations (2 µM) (Figure 21, Panel C). The same results were evident when 
we calculated the p-tau/total tau (tau5) ratios (Figure 21, Panels D and E). 
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Figure 21. Relative levels of total tau and p-tau cortical synaptosome-enriched fractions. (A) total-tau 
detected with tau5 antibody. (B) p-tau at Ser262 was detected using the p-tau Ser262 antibody. (C) p-tau at 
Ser202 and Thr205 was detected using the AT8 antibody. (D) p-tau (Ser262)/total tau (tau5) ratio. (E) p-tau 
(Ser202 and Thr205)/total tau (tau5) ratio. Values shown represent percentage of the control. Data were 
obtained from two independent experiments (n = 2). 
 
 
4.3.2. Hippocampal synaptosome-enriched fractions 
 
 All procedures described for cortical synaptosome-enriched fractions were 
identical to those used with hippocampal synaptosome-enriched fractions. Therefore, 
effects of Abeta1-42 treatment on APP and tau phosphorylation were also addressed. 
 
 
4.3.2.1. APP phosphorylation 
 
 The levels of holo-APP in hippocampal synaptosome-enriched fractions did not 
change upon exposure to increasing concentrations of Abeta1-42. The results of APP 
phosphorylation at the Thr668 residue are presented in Figure 22 Panel C, and showed an 
accentuated increase on APP phosphorylation with lower Abeta1-42 concentrations (0,25 
µM and 0,5 μM), and diminished increase with higher Abeta1-42 concentrations (2 µM). In 
Figure 22 Panel D is presented the p-APP (Thr668)/holo-APP (C-Terminal) ratio, which 
clearly shows an increase on APP phosphorylation at Thr668 residue, particularly with 0,5 
µM Abeta1-42 concentration. 
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Figure 22. Relative levels of holo-APP (C-Terminal and N-Terminal) and p-APP (Thr668) in hippocampal 
synaptosomes. (A) holo-APP detected with 22C11 antibody. (B) holo-APP detected with C-Terminal 
antibody. (C) p-APP (Thr668) detected using a phosphorylation-specific antibody against Thr668. (D) p-APP 
(Thr668)/holo-APP (C-Terminal) ratio. Values shown represent percentage of the control. Data were 
obtained from two independent experiments (n = 2). 
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4.3.2.2. Tau phosphorylation 
 
 The levels of total tau on hippocampal synaptosome-enriched fractions treated 
with different Abeta1-42 concentrations (Figure 23 Panel A) revealed a slight increase. Tau 
phosphorylation at Ser262 residue (Figure 23, Panel B) increased marginally with the 
lowest Abeta1-42 concentration (0,25 µM), but at 0,5 µM of Abeta1-42 tau phosphorylation 
increased significantly (Figure 23, Panel B). The p-tau (Ser262)/total tau (tau5) ratio 
(Figure 23, Panel C) showed an increase in tau phosphorylation at Ser262 residue upon 
treatment with the toxic Abeta1-42 peptide with the two higher concentrations of (0,5 and 
2 µM). 
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Figure 23. Relative levels of total tau and p-tau hippocampal synaptosome-enriched fractions. (A) total-
tau detected with tau5 antibody. (B) p-tau at Ser262 was detected using the p-tau Ser262 antibody. (C) p-
tau (Ser262)/total tau (tau5) ratio. Values shown represent percentage of the control. Data were obtained 
from two independent experiments (n = 2). 
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5. DISCUSSION 
 
 Abeta is the major player associated with AD pathology, being considered purely 
toxic until very recently. Several studies have now that Abeta has important physiological 
functions, mostly related with synaptic activity and neuronal cell survival (Plant et al., 
2003; Steinbach et al., 1998; Yu, 2003). Another interesting aspect related with Abeta 
biology is its relationship with tau, and has been proposed that Abeta might trigger 
several intracellular alterations namely activation and/or inactivation of PKs and PPs that 
result in tau hyperphosphorylation and neuronal death consistent with 
neurodegeneration observed in AD pathology (Citron, 2004; Hardy and Selkoe, 2002). 
Therefore these mechanisms, potentially mediated by Abeta deserve further 
investigation. We addressed the effects of Abeta on APP phosphorylation at Thr668 
residue and tau phosphorylation at Ser202, Thr205 and Ser262 residues. All these 
residues are relevant for AD since APP was found phosphorylated in AD brains (Lee et al., 
2003), namely at Thr668 residue, and tau residues were reported to be 
hyperphopshorylated in earlier stages of AD (Augustinack et al., 2002; Bertrand et al., 
2010; Kimura et al., 1996). In addition, Ser262 has been proposed to be more injurious 
than other sites, since it is localized within microtubule-binding domain of tau protein 
altering its biological functions associated with binding and stabilization of microtubules.  
 The selection of the model system for these Abeta studies was of paramount 
importance. Cortical and hippocampal synaptosomes represent a very attractive model 
system since the synaptic function is maintained with intact biochemical, 
electrophysiological and morphological properties. Additionally, the use of synaptosomes 
allows the synapse to be studied in situ. Hence, developing a protocol to successfully 
obtain synaptosome-enriched fractions was the first step of the work outlined. The 
protocol started with cortex and hippocampus homogenates from rat brain. Each 
homogenate was subjected to a series of centrifugations culminating in a Percoll® 
gradient fractionation. During the isolation protocol several samples from the 
intermediate products were collected, namely the homogenate (H), supernatant from the 
second centrifugation (S2), inferior fraction after Percoll® ressuspension and supernatants 
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from washing steps (Sn) and the synaptosomal fraction (Syn). After analysis of those 
fractions we verified that cortical and hippocampal synaptosomal fractions (Syn) were 
enriched in both synaptophysin and PSD-95 proteins (Figure 16 and Figure 17). 
Surprisingly, the levels of ATP synthase α were high, indicating that our synaptosomal 
fractions have some degree of contamination (Figure 16 and Figure 17). Nonetheless, high 
enrichment of synaptosomal fractions with pre- and post-synaptic markers also indicated 
that we were in the presence of synaptosome-enriched fractions and not purified 
synaptosomal fractions. Consequently, our first objective was accomplished and those 
fractions were used for further studies. Prior to determination of the effects of Abeta1-42 
treatment on APP and tau phosphorylation, we went on to test if the different Abeta1-42 
concentrations used produced alterations on synaptosomal viability. This evaluation was 
important since it indicates whether synaptosomes are still under physiological 
conditions, or if they are entering cell death due to extreme non-physiological conditions. 
Exposure of cortical and hippocampal synaptosome-enriched fractions to Abeta1-42 
provoked a slight decrease in the percentage of viable cells (Figure 18 and Figure 19). 
However, a robust decrease in the percentage of viable cells is observed upon Abeta1-42 
(0,25 µM) treatment of hippocampal synaptosome-enriched fractions. We considered 
that additional experiments should be performed to confirm this decrease. In overall, we 
conclude that all Abeta concentrations did not dramatically reduced synaptosome-
enriched fractions viability. Similar results were observed in a study conducted by Canas 
et al., in which synaptosomes were incubated with 0,05 µM Abeta1-42 for two hours 
(Canas et al., 2009), which produced a decrease on synaptosomal viability by 
approximately 10 %. 
 Exposure of cortical and hippocampal synaptosome-enriched fractions to Abeta1-42 
induced responses on APP phosphorylation. In cortical synaptosome-enriched fractions 
we observed a robust increase on APP phosphorylation at 0,25 µM and 0,5 µM Abeta 
concentrations (Figure 20, Panel C). In contrast, when using hippocampal synaptosome-
enriched fractions, the increase on APP phosphorylation at Thr668 residue was more 
generalized and observed with all Abeta1-42 concentrations tested (Figure 22, Panel C). 
The results presented so far strongly suggest that Abeta1-42 can induce APP 
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phosphorylation; however, more independent experiments must be performed, specially 
using hippocampal synaptosome-enriched fractions. 
 The treatment of both cortical and hippocampal synaptosome-enriched fractions 
with Abeta1-42 provoked responses in terms of tau phosphorylation, which appear to be 
consistent with AD pathology. The tau phosphorylation profiles of Ser202, Thr205 
(analyzed together) and Ser262 residues were quite different upon exposure to Abeta and 
are also different depending on the region under analysis (cortex and hippocampus). 
Hence, a slight increase in tau phosphorylation at Ser262 (Figure 21, Panel B) was 
observed when cortical synaptosome-enriched fractions were used and a robust increase 
in tau phosphorylation with 0,5 µM of Abeta1-42 (Figure 23, Panel B). The profile of the 
Ser202 and Thr205 in cortical fractions was quite different. An increase on tau 
phosphorylation was observed with lower Abeta concentrations (0,25 µM and 0,5 µM, 
Figure 21, Panel C). We were unable to detect tau phosphorylation of these residues in 
hippocampal synaptosome-enriched fractions. Data regarding tau phosphorylation 
strongly suggests that Abeta1-42 induces tau phosphorylation of the above mentioned 
residues.  
 Overall, it is evident that APP and tau phosphorylation can be modulated by 
Abeta1-42. It is reasonable to deduce that the latter is affecting specific signaling cascades 
which are modulated by protein phosphorylation/dephosphorylation events that 
culminate with APP and tau phosphorylation. Our results mimicked the current AD 
pathology model, where APP is found phosphorylated on several residues including 
Thr668 and that Abeta1-42 deposits on APs precede the NFTs, which results from 
abnormally phosphorylation events of tau protein. Given the importance of protein 
phosphorylation in AD pathology, it is reasonable to assume that additional work should 
be performed in order to clarify the PKs and PPs involved in those 
phosphorylations/dephosphorylations events. 
 The findings obtained from this dissertation are important in terms of 
understanding the basic molecular and cellular mechanisms relevant to Alzheimer’s 
disease. 
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6. CONCLUDING REMARKS 
 
• Cortical and hippocampal synaptosomal fractions were enriched in pre- and post-
synaptic proteins; 
• Cortical and hippocampal synaptosomal fractions present a high number of 
mitochondria; 
• The isolation procedure was efficient and produced cortical and hippocampal 
synaptosome-enriched fractions; 
• Abeta1-42 treatment of cortical and hippocampal synaptosome-enriched fractions 
did not did dramatically decreased their viability; 
• Holo-APP levels did not change in response to Abeta1-42 exposure; 
• Abeta1-42 treatment of cortical synaptosome-enriched fractions produced an 
increase on APP phosphorylation at Thr668 residue, particularly with 0,25 and 0,5 
µM; 
• Total-tau levels in cortical synaptosome-enriched fractions did not change in 
response to Abeta; 
• Abeta1-42 treatment of cortical synaptosome-enriched fractions produced a slight 
increase on tau phosphorylation at Ser262 residue; 
• 0,25 µM and 0,5 µM of Abeta1-42 treatment of cortical synaptosome-enriched 
fractions induced tau phosphorylation at Ser202 and Thr205 residues; 
• Total tau levels, in hippocampal synaptosome-enriched fractions, slightly 
increased in response to Abeta; 
• Hippocampal synaptosome-enriched fractions exposed to Abeta1-42 produced an 
increase on APP phosphorylation at Thr668 residue; 
• Abeta1-42 (0,5 µM and 2 µM) treatment of hippocampal synaptosome-enriched 
fractions increased tau phosphorylation at Ser262 residue. 
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APPENDIX 
 
I. Synaptosome isolation solutions 
 
1 M Sucrose 
• Sucrose 34,23 g 
Mix until the solute has dissolved. Adjust the final volume to 100 mL deionised H2O and 
store at 4
o
 C. 
 
0,1 M Tris 
• Tris  1,2114 g 
Mix until the solute has dissolved. Adjust the final volume to 100 mL deionised H2O and 
store at 4
o
 C. 
 
0,02 M Ethylene glycol tetraacetic acid (EGTA) 
• EGTA 0,7608 g 
Mix until the solute has dissolved. Adjust the final volume to 100 mL deionised H2O and 
store at 4
o
 C. 
 
0,01 M Dithiothreitol (DTT) 
• DTT 0,0030 g 
Mix until the solute has dissolved. Adjust the final volume to 2 mL deionised H2O and 
store at 4
o
 C. Discard the solution if it is stored for more than 24 hours. 
 
0,2 M NaCl 
• NaCl 1,1688 g 
Mix until the solute has dissolved. Adjust the final volume to 100 mL deionised H2O and 
store at 4
o
 C. 
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0,01 M KCl 
• KCl 0,0745 g 
Mix until the solute has dissolved. Adjust the final volume to 100 mL deionised H2O and 
store at 4
o
 C. 
 
0,05 M HEPES 
• HEPES 1,3015 g 
Mix until the solute has dissolved. Adjust the final volume to 100 mL deionised H2O and 
store at 4
o
 C. 
 
0,01 M EDTA 
• EDTA 0,3722 g 
Mix until the solute has dissolved. Adjust the final volume to 100 mL deionised H2O and 
store at 4
o
 C. 
 
0,02 M Glucose 
• Glucose 0,3604 g 
Mix until the solute has dissolved. Adjust the final volume to 100 mL deionised H2O and 
store at 4
o
 C. 
 
Homogenizing buffer 
• 1 M Sucrose solution  16 mL (0,32 M) 
• 0,1 M Tris solution  25 mL (0,05 M) 
• 0,02 M EGTA solution  5 mL (0,002 M) 
• 0,01 M DTT solution  5 mL (0,001 M) 
Prepare the solution just prior to use. Adjust the pH to 7.6 and store at 4
o
 C. 
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Krebs buffer 
• 0,2 M NaCl solution  11,2 mL (0,14 M) 
• 0,01 KCl solution  8 mL (0,005 M) 
• 0,05 HEPES solution  8 mL (0,025 M) 
• 0,01 EDTA solution  1,6 mL (0,001 M) 
• 0,02 Glucose solution  8 mL (0,01 M) 
Prepare the solution just prior to use. Adjust the pH to 7.4 and store at 4
o
 C. 
 
Percoll® 45% (v/v) 
• Percoll® 2,7 mL 
• Krebs buffer 3,3 mL 
Prepare the solution just prior to use and store at 4
o
 C. 
 
II. SDS-PAGE and Immunoblotting Solutions 
 
4x Lower Gel Buffer (LGB) 
  
To 900 mL of deionised H2O add: 
• Tris 181,65 g (1,5 M) 
• SDS 4 g (0,4%) 
Mix until the solutes have dissolved. Adjust the pH to 8.9 and the final volume to 1 L with 
deionised H2O. Store at 4
o
 C. 
 
4x Upper Gel Buffer (0,5 M Tris, 0,4% SDS) 
 
To 900 mL of deionised H2O add: 
• Tris 75,9 g (0,5 M) 
• SDS 4 g (0,4%) 
Mix until the solutes have dissolved. Adjust the pH to 6.8 with HCl and the volume to 1 L 
with deionised H2O. Store at 4
o
 C. 
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30% Acrylamide/0,8% Bisacrylamide 
 
To 70 mL of deionised H2O add: 
• Acrylamide 29.2 g 
• Bisacrylamide 0,8 g 
Mix until the solutes have dissolved. Adjust the volume to 100 mL with deionised H2O. 
Filter through a 0,2 μm filter and store at 4
o
 C. 
 
10% Ammonium persulfate (APS) 
 
In 10 mL of deionised H2O dissolve 1 g of APS. Store at 4
o
 C. 
 
10% Sodium dodecilsulfate (SDS) 
 
In 10 mL of deionised H2O dissolve 1 g of SDS. Store the solution at room temperature. 
 
1 M Tris (pH 6.8) 
 
To 150 mL of deionised H2O add: 
• Tris base 30,3 g 
Adjust the pH to 6.8 with HCl and the final volume to 250 mL with deionised H2O. Store at 
4
o
 C. 
 
Loading Gel Buffer (4x) 
 
• 1 M Tris solution (pH 6.8) 2,5 mL (250 mM) 
• SDS    0,8 g (8%) 
• Glycerol   4 mL (40%) 
• β-Mercaptoethanol  2 mL (2%) 
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• Bromophenol blue  1 mg (0,01 %) 
Adjust the volume to 10 mL with deionised H2O and store in darkness at room 
temperature. 
 
10x Running Buffer 
 
• Tris  30,3 g (250 mM) 
• Glycine 144,2 g (2.5 M) 
• SDS  10 g (1%) 
Dissolve in deionised H2O. Adjust the pH to 8.3 with HCl and the final volume to 1 L. Store 
at room temperature. 
 
1x Transfer Buffer 
 
• Tris  3.03 g (25 mM) 
• Glycine 14,41 g (192 mM) 
Mix until solutes dissolve. Adjust the pH to 8.3 with HCl and the final volume to 800 mL 
with deionised H2O. Just prior to use add 200 mL of methanol (20%). Store the solution at 
room temperature. 
 
10x Tris Buffered Saline (TBS) 
 
• Tris 12,11 g (10 mM) 
• NaCl 87,66 g (150 mM) 
Adjust the pH to 8.0 with HCl and adjust the final volume to 1 L with deionised H2O. Store 
at 4
o
 C. 
 
10x Tris Buffered Saline with Tween 20 (TBS-T) 
 
• Tris  12,11 g (10 mM) 
  
University of Aveiro – Masters in Molecular Biomedicine 
Centre for Cell Biology 
2011 
 
88 
 
 
 
• NaCl  87,66 g (150 mM) 
• Tween 20 5 mL (0,05 %) 
Adjust the pH to 8.0 with HCl and adjust the final volume to 1 L with deionised H2O. Store 
at 4
o
 C. 
